非选择性β受体阻滞剂与肝硬化危重患者死亡率降低相关:一项真实世界研究
该真实世界研究将108例入院前使用非选择性β受体阻滞剂(NSBB)的急性失代偿(AD)肝硬化ICU患者与108例未使用者进行倾向性评分匹配,发现NSBB组28天和90天死亡率显著更低,且全身炎症标志物更低,提示NSBB可能通过减轻炎症反应改善生存。
要点
- 倾向性评分匹配后,NSBB组28天死亡率显著低于非NSBB组(p=0.001),90天死亡率亦显著更低(p=0.002)。
- 入住ICU时,NSBB组心率、血小板、白细胞计数、中性粒细胞与淋巴细胞比值及C反应蛋白均低于非NSBB组。
- 多因素分析显示,入院时慢加急性肝衰竭(ACLF)和社区获得性细菌感染是28天死亡率的独立负性预测因素,而既往使用NSBB是生存的正性预测因素。
核心结论
- 在需要ICU入院的急性失代偿肝硬化危重患者中,既往使用NSBB与28天和90天死亡率改善相关,其机制可能部分通过减轻炎症反应介导。
研究设计与样本
- 真实世界研究,从需要ICU入院的急性失代偿肝硬化患者登记中招募;共445例患者中,108例入院前使用NSBB者按年龄、性别、入院前Child-Turcotte-Pugh评分和既往失代偿史与108例未使用NSBB者进行倾向性评分匹配,后者为对照组。
主要发现
- 匹配后两组肝硬化病因或急性失代偿诱因无差异;入院前肌酐、胆红素、国际标准化比值和血红蛋白相似,而NSBB组入院前白细胞计数和中性粒细胞与淋巴细胞比值较低。
- 入住ICU时,NSBB组心率(p=0.006)、血小板(p=0.012)、白细胞计数(p=0.006)、中性粒细胞与淋巴细胞比值(p=0.039)和C反应蛋白(p=0.007)均较低。
- 非NSBB组社区获得性细菌感染(p=0.006)、肾衰竭(p=0.033)和更高级别慢加急性肝衰竭(ACLF;p=0.012)显著更多。
- NSBB组28天死亡率(p=0.001)和90天死亡率(p=0.002)均显著更低。
- 28天死亡率单因素和多因素分析显示,入院时ACLF和社区获得性细菌感染是独立负性预测因素,而既往使用NSBB是生存的正性预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apart from direct portal pressure reduction, non-selective beta-blockers (NSBB) modulate inflammatory response, which could be beneficial in patients with acute decompensation (AD). We therefore aimed to evaluate the effect of NSBB on 28-day mortality and markers of systemic inflammation in a propensity score-matched (PSM) cohort of AD patients requiring intensive care unit (ICU) admission. METHODS: Patients were recruited from registry of AD patients requiring ICU admission. Out of total 445 patients, 108 patients on NSBB before admission (NSBB use group) were PSM for age, gender, pre-admission Child-Turcotte-Pugh score and history of previous decompensation to 108 patients not on NSBB (non-NSBB use group) which served as the control group. ICU parameters, markers of systemic inflammation and 28-day mortality were compared by standard statistical tests. RESULTS: After PSM, no difference was observed in aetiology of cirrhosis, or precipitating event for AD between the groups. Pre-admission creatinine, bilirubin, international normalised ratio and haemoglobin were similar between the groups, whereas pre-admission white cell count (WCC) and neutrophil to lymphocyte ratio (NLR) was lower in NSBB-group. On admission to ICU, NSBB group had lower heart rate (p = 0.006), platelets (p = 0.012), WCC (p = 0.006), NLR (p = 0.039) and C-reactive protein (p = 0.007). Significantly more community acquired bacterial infections (p = 0.006), renal failure (p = 0.033) and higher grades of acute-on-chronic liver failure (ACLF; p = 0.012) were observed in non-NSBB group. Significantly lower 28-day (p = 0.001) and 90-day (p = 0.002) mortality was seen in NSBB group. Univariate and multivariable analysis for 28-day mortality showed that while ACLF at presentation and community acquired bacterial infection were independent negative predictors, prior NSBB use was positive predictors of survival. CONCLUSIONS: Prior use of NSBB is associated with improved 28- and 90-day mortality in critically ill cirrhosis patients with AD which is mediated probably by blunting of the inflammatory response.
引用
- Kumar R, Lin S, Mehta G, et al. Non-selective beta-blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real-world study. Aliment Pharmacol Ther. 2024. PMID: 39091108. doi:10.1111/apt.18188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。